OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nicholas A. Vitanza, Adam Johnson, Ashley Wilson, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1544-1552
Closed Access | Times Cited: 218
Nicholas A. Vitanza, Adam Johnson, Ashley Wilson, et al.
Nature Medicine (2021) Vol. 27, Iss. 9, pp. 1544-1552
Closed Access | Times Cited: 218
Showing 1-25 of 218 citing articles:
CAR immune cells: design principles, resistance and the next generation
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 339
Louai Labanieh, Crystal L. Mackall
Nature (2023) Vol. 614, Iss. 7949, pp. 635-648
Closed Access | Times Cited: 339
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 724-734
Open Access | Times Cited: 307
Vivek Narayan, Julie S. Barber-Rotenberg, In-Young Jung, et al.
Nature Medicine (2022) Vol. 28, Iss. 4, pp. 724-734
Open Access | Times Cited: 307
CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 289
Karama Makni‐Maalej, Maysaloun Merhi, Varghese Inchakalody, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 289
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute, et al.
Nature Reviews Clinical Oncology (2022) Vol. 20, Iss. 1, pp. 49-62
Open Access | Times Cited: 243
Christian Flugel, Robbie G. Majzner, Giedre Krenciute, et al.
Nature Reviews Clinical Oncology (2022) Vol. 20, Iss. 1, pp. 49-62
Open Access | Times Cited: 243
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Nicholas A. Vitanza, Ashley Wilson, Wenjun Huang, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 114-131
Open Access | Times Cited: 169
Nicholas A. Vitanza, Ashley Wilson, Wenjun Huang, et al.
Cancer Discovery (2022) Vol. 13, Iss. 1, pp. 114-131
Open Access | Times Cited: 169
Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Qing Wu, Wei Qian, Xiaoli Sun, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 135
Next-Generation CAR T-cell Therapies
Regina M. Young, Nils W. Engel, Uğur Uslu, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1625-1633
Open Access | Times Cited: 125
Regina M. Young, Nils W. Engel, Uğur Uslu, et al.
Cancer Discovery (2022) Vol. 12, Iss. 7, pp. 1625-1633
Open Access | Times Cited: 125
Glioma
Michael Weller, Patrick Y. Wen, Susan M. Chang, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 120
Michael Weller, Patrick Y. Wen, Susan M. Chang, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 120
CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma
Guoqing Wang, Zongliang Zhang, Kunhong Zhong, et al.
Molecular Therapy (2022) Vol. 31, Iss. 1, pp. 134-153
Open Access | Times Cited: 116
Guoqing Wang, Zongliang Zhang, Kunhong Zhong, et al.
Molecular Therapy (2022) Vol. 31, Iss. 1, pp. 134-153
Open Access | Times Cited: 116
Nanobody-based CAR-T cells for cancer immunotherapy
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 106
Pouya Safarzadeh Kozani, Abdolhossein Naseri, Seyed Mohamad Javad Mirarefin, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 106
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 102
Amin Daei Sorkhabi, Leila Mohamed Khosroshahi, Aila Sarkesh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 102
Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial
Christine E. Brown, Jonathan Hibbard, Darya Alizadeh, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1001-1012
Open Access | Times Cited: 96
Christine E. Brown, Jonathan Hibbard, Darya Alizadeh, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1001-1012
Open Access | Times Cited: 96
Current updates on generations, approvals, and clinical trials of CAR T-cell therapy
Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 95
Tadesse Asmamaw Dejenie, Markeshaw Tiruneh G Medhin, Gashaw Dessie Terefe, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 6
Open Access | Times Cited: 95
CAR-T Therapies in Solid Tumors: Opportunities and Challenges
Grace Guzman, Megan R. Reed, Kevin Bielamowicz, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 5, pp. 479-489
Open Access | Times Cited: 83
Grace Guzman, Megan R. Reed, Kevin Bielamowicz, et al.
Current Oncology Reports (2023) Vol. 25, Iss. 5, pp. 479-489
Open Access | Times Cited: 83
Tumor inflammation-associated neurotoxicity
Jasia Mahdi, Jörg Dietrich, Karin Straathof, et al.
Nature Medicine (2023) Vol. 29, Iss. 4, pp. 803-810
Open Access | Times Cited: 63
Jasia Mahdi, Jörg Dietrich, Karin Straathof, et al.
Nature Medicine (2023) Vol. 29, Iss. 4, pp. 803-810
Open Access | Times Cited: 63
Metabolic challenges and interventions in CAR T cell therapy
Jhan-Jie Peng, Limei Wang, Zhiyu Li, et al.
Science Immunology (2023) Vol. 8, Iss. 82
Closed Access | Times Cited: 59
Jhan-Jie Peng, Limei Wang, Zhiyu Li, et al.
Science Immunology (2023) Vol. 8, Iss. 82
Closed Access | Times Cited: 59
Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
Michael C. Burger, Marie-Thérèse Forster, A Romański, et al.
Neuro-Oncology (2023) Vol. 25, Iss. 11, pp. 2058-2071
Open Access | Times Cited: 50
Michael C. Burger, Marie-Thérèse Forster, A Romański, et al.
Neuro-Oncology (2023) Vol. 25, Iss. 11, pp. 2058-2071
Open Access | Times Cited: 50
Recurrent Glioblastoma: A Review of the Treatment Options
Maria Angeles Vaz-Salgado, María Villamayor, Víctor Albarrán, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4279-4279
Open Access | Times Cited: 49
Maria Angeles Vaz-Salgado, María Villamayor, Víctor Albarrán, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4279-4279
Open Access | Times Cited: 49
IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM
Μαρκέλλα Ζαννίκου, Joseph Duffy, Rebecca Levine, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e006239-e006239
Open Access | Times Cited: 43
Μαρκέλλα Ζαννίκου, Joseph Duffy, Rebecca Levine, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 2, pp. e006239-e006239
Open Access | Times Cited: 43
Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma
Uğur Uslu, Tong Da, Charles‐Antoine Assenmacher, et al.
Science Advances (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 42
Uğur Uslu, Tong Da, Charles‐Antoine Assenmacher, et al.
Science Advances (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 42
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 32
Lei Peng, Giacomo Sferruzza, Luojia Yang, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 10, pp. 1089-1108
Open Access | Times Cited: 32
Immune evasion of dormant disseminated tumor cells is due to their scarcity and can be overcome by T cell immunotherapies
Erica T. Goddard, Miles H. Linde, Shivani Srivastava, et al.
Cancer Cell (2024) Vol. 42, Iss. 1, pp. 119-134.e12
Open Access | Times Cited: 23
Erica T. Goddard, Miles H. Linde, Shivani Srivastava, et al.
Cancer Cell (2024) Vol. 42, Iss. 1, pp. 119-134.e12
Open Access | Times Cited: 23
Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial
Meenakshi Hegde, Shoba A. Navai, Christopher DeRenzo, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 880-894
Open Access | Times Cited: 22
Meenakshi Hegde, Shoba A. Navai, Christopher DeRenzo, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 880-894
Open Access | Times Cited: 22
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors
Frank Y. Lin, Austin J. Stuckert, Candise Tat, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2769-2779
Open Access | Times Cited: 22
Frank Y. Lin, Austin J. Stuckert, Candise Tat, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 23, pp. 2769-2779
Open Access | Times Cited: 22
A new era of cancer immunotherapy: combining revolutionary technologies for enhanced CAR-M therapy
Na Li, Shinan Geng, Zhenzhen Dong, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 20
Na Li, Shinan Geng, Zhenzhen Dong, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 20
